BCL2 and Miyoshi myopathy: Furthermore, AMG9810 treatment dose-dependently decreased the levels of the anti-apoptotic proteins BCL-2 and MCL-1 and the phosphorylation of mTOR target, pro-survival factor pS6, in MM cells (Fig. 1e).